Istari Oncology, Inc.

Recurrent glioblastoma tumors with fewer mutations respond better to immunotherapies, offering longer survival for some patients. Duke researchers suggest chemotherapy may prime tumors for immunotherapy, potentially aiding in developing more effective treatments.